AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MESOBLAST LTD

1.610

-0.040-2.42%

Volume:8.04M

Turnover:12.64M

Market Cap:2.04B

PE:-11.20

High:1.615

Open:1.600

Low:1.520

Close:1.650

Loading ...

Overview Company News Filings

Mesoblast Expands Insurance Coverage for Ryoncil to 104 Million Lives in US

MT Newswires Live

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Here are the top 10 ASX 200 shares today

Here are the ASX 200 shares leading Tuesday's market rebound

Stock Track | Mesoblast Shares Soar 5.26% on Positive Outlook for Ryoncil Launch and Broker Upgrade

Stock Track | Mesoblast Soars 5.26% as Ryoncil Launch and Positive Broker Outlook Boost Investor Confidence

Top broker says Mesoblast shares can rocket 100%

Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares

ASX 200 plunges as US tariffs fall-out continues

Friday’s HotCopper Trends: Mesoblast dodges tariffs, Orthocell’s FDA tick | April 4, 2025

The Market Herald

BRIEF-Mesoblast Says Mesoblast Cell Therapy Products Not Subject To U.S. Tariffs

Mesoblast Says Products Exempt From US Tariffs

MT Newswires Live

BRIEF-Mesoblast Says Allogeneic Cell Therapy Products Are Designated ‘U.S. Country Of Origin’ And Not Subject To U.S. Tariffs

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs

THOMSON REUTERS

Mesoblast Ltd - Cell Therapy Products Not Subject to U.S. Tariffs

THOMSON REUTERS

Mesoblast - Allogeneic Cellular Products, Including Ryoncil and Revascor, Will Not Be Subject to Tariffs

THOMSON REUTERS

Mesoblast Seeks US FDA Meeting to Discuss Approval for Heart Failure Drug Candidate

MT Newswires Live

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Mesoblast (ASX:MSB) Announces Ryoncil Availability But Sees 15% Price Drop Over Past Week

Simply Wall St.

BRIEF-Mesoblast Says Co Entered Medicaid National Drug Rebate Agreement With US CMS For Ryoncil

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSB.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":1.61,"timestamp":1745302320000,"preClose":1.65,"halted":0,"volume":8037648,"delay":0,"nameEN":"MESOBLAST LTD","floatShares":777083698,"shares":1269984284,"eps":-0.1437297482552343,"marketStatus":"Closed","change":-0.04,"latestTime":"04-22 16:12:00 AEST","open":1.6,"high":1.615,"low":1.52,"amount":12639016,"amplitude":0.057576,"askPrice":1.62,"askSize":54061,"bidPrice":1.61,"bidSize":3251,"shortable":3,"etf":0,"ttmEps":-0.1437297482552343,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":1.65,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":1.104736,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":777083698,"roa":"-4.85%","roe":"-21.31%","lyrEps":-0.138866,"volumeRatio":1.104736,"shares":1269984284,"dividePrice":0,"high":1.615,"amplitude":0.057576,"preClose":1.65,"low":1.52,"week52Low":0.76,"pbRate":"2.85","psRate":"231.48","week52High":3.37,"institutionHeld":0,"latestPrice":1.61,"committee":-0.886551,"eps":-0.1437297482552343,"divideRate":0,"volume":8037648,"delay":0,"ttmEps":-0.1437297482552343,"open":1.6,"prevYearClose":3.1,"prevWeekClose":1.65,"prevMonthClose":1.96,"prevQuarterClose":1.96,"fiveDayClose":1.575,"twentyDayClose":2.24,"sixtyDayClose":2.77},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2528732243","title":"Mesoblast Expands Insurance Coverage for Ryoncil to 104 Million Lives in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2528732243","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528732243?lang=en_us&edition=fundamental","pubTime":"2025-04-17 12:23","pubTimestamp":1744863798,"startTime":"0","endTime":"0","summary":"Mesoblast  expanded its coverage for Ryoncil to 104 million US government- and private-insured lives, according to a Thursday filing with the Australian bourse.Ryoncil is approved by the US Food and Drug Administration for mesenchymal stromal cell therapy.It is the only approved therapy for steroid-refractory acute graft versus host disease  in children aged two months and older, a separate filing showed.Mesoblast's shares were up nearly 2% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","MESO","MSB.AU","BK7067","BK7501","BK4139"],"gpt_icon":0},{"id":"2528842107","title":"Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives","url":"https://stock-news.laohu8.com/highlight/detail?id=2528842107","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528842107?lang=en_us&edition=fundamental","pubTime":"2025-04-17 09:20","pubTimestamp":1744852800,"startTime":"0","endTime":"0","summary":"NEW YORK, April 16, 2025  -- Mesoblast , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand coverage for Ryoncil , the first mesenchymal stromal cell  therapy approved by U.S. Food and Drug Administration  for any indication, to 104 million US lives insured by government and commercial payers.Mesoblast’s RYONCIL  for the treatment of steroid-refractory acute graft versus host disease  in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell  therapy. Please see the full Prescribing Information at www.ryoncil.com.About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercia","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-extends-payer-coverage-ryoncil-012000537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSB.AU","BK4139","BK4575","MSC","BK4150","MSB","MESO","BK4006"],"gpt_icon":0},{"id":"2527186297","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2527186297","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527186297?lang=en_us&edition=fundamental","pubTime":"2025-04-14 15:01","pubTimestamp":1744614107,"startTime":"0","endTime":"0","summary":"It was a flying start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. After a rough end to last week, investors came back from the weekend with a spring in their steps. By the ti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/14/here-are-the-top-10-asx-200-shares-today-14-april-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SMR.AU","BK7067","XJO.AU","BK7504","PME.AU","NEU.AU","PNV.AU","BK7501","BK7129","BK7016","WHC.AU","BK7507","CU6.AU","SDR.AU","BK7083","MSB.AU","BK7096","BK7126","BK7094","BK7062","PNI.AU","BK7095","BK7508","MIN.AU"],"gpt_icon":0},{"id":"2525381656","title":"Here are the ASX 200 shares leading Tuesday's market rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=2525381656","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525381656?lang=en_us&edition=fundamental","pubTime":"2025-04-08 10:07","pubTimestamp":1744078054,"startTime":"0","endTime":"0","summary":"S&P/ASX 200 Index (ASX: XJO) shares are rebounding, currently up 1.4% to 7,449.1 points at the time of writing.  Today's rebound follows a horror day on the market yesterday.  ASX 200 shares fell to t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/08/here-are-the-asx-200-shares-leading-tuesdays-market-rebound/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7110","LTR.AU","BK7501","MSB.AU","BK7051","BK7126","XYZ.AU","BK7507","ZIP.AU","360.AU","BK7016","BK7158","BK7508","BK7094","PME.AU","XJO.AU","WHC.AU","CSC.AU","BK7093","PNV.AU","BK7067","BK7083","BK7095","BK7504","AOV.AU"],"gpt_icon":0},{"id":"1184927466","title":"Stock Track | Mesoblast Shares Soar 5.26% on Positive Outlook for Ryoncil Launch and Broker Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1184927466","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184927466?lang=en_us&edition=fundamental","pubTime":"2025-04-08 08:10","pubTimestamp":1744071028,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd  shares are soaring 5.26% in intraday trading on Tuesday, as investors react positively to recent developments and a bullish broker report. The biotechnology company's stock price jump comes amid growing optimism surrounding the launch of its lead product, Ryoncil, in the United States.Adding to the positive sentiment, leading broker Bell Potter has maintained a speculative buy rating on Mesoblast shares with a price target of $3.40, implying potential upside of over 100%. The brok","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Mesoblast Shares Soar 5.26% on Positive Outlook for Ryoncil Launch and Broker Upgrade","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"gpt_icon":0},{"id":"1179227659","title":"Stock Track | Mesoblast Soars 5.26% as Ryoncil Launch and Positive Broker Outlook Boost Investor Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=1179227659","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179227659?lang=en_us&edition=fundamental","pubTime":"2025-04-08 08:10","pubTimestamp":1744071028,"startTime":"0","endTime":"0","summary":"Shares of Mesoblast Ltd  surged 5.26% in Tuesday's trading session, following positive developments in the company's commercialization efforts for its lead product, Ryoncil, and an optimistic outlook from a top broker.The biotech company has made significant strides in launching Ryoncil, its treatment for steroid-refractory acute graft versus host disease  in children, in the United States. Key achievements include the product's inclusion in major US drug pricing compendia and a National Drug Re","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"gpt_icon":0},{"id":"2525072189","title":"Top broker says Mesoblast shares can rocket 100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2525072189","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525072189?lang=en_us&edition=fundamental","pubTime":"2025-04-08 05:01","pubTimestamp":1744059680,"startTime":"0","endTime":"0","summary":"It has been a bruising ride for Mesoblast Ltd  shares in recent weeks, but if one leading broker is to be believed, the beaten-down biotech company could deliver some serious upside for investors. That's the view of analysts at Bell Potter, which are feeling upbeat on the company's prospects now that its Ryoncil product has hit the market. What is the broker say about Mesoblast shares?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/08/top-broker-says-mesoblast-shares-can-rocket-100/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4139","BK7067","BK7501","MSB.AU","BK4082","MESO","NDRA","BK7508"],"gpt_icon":0},{"id":"2525222758","title":"Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2525222758","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525222758?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:00","pubTimestamp":1743796800,"startTime":"0","endTime":"0","summary":"ASX share Opthea Limited (ASX: OPT)remains suspended from trading as the biotechcompany works to avoid insolvency.  Opthea last traded at 60 cents per share.   Last week, we learned that Opthea has de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/05/broker-laments-catastrophic-negative-surprise-that-highlights-the-risks-with-these-types-of-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MSB.AU","BK7501","CSL.AU","BK7508","BK7067","OPT.AU","BK7511","OPT","BK4139","XJO.AU"],"gpt_icon":0},{"id":"2524279082","title":"ASX 200 plunges as US tariffs fall-out continues","url":"https://stock-news.laohu8.com/highlight/detail?id=2524279082","media":"MotleyFool","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524279082?lang=en_us&edition=fundamental","pubTime":"2025-04-04 14:00","pubTimestamp":1743746431,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index  plummeted by 191.9 points or 2.44% on Friday to finish the week at 7,667.8 points.Uncertainty about how the newly announced reciprocal US tariffs will impact ASX 200 shares fuelled today's dive.Based on closing values, today's market rout has pushed the ASX 200 into an official market correction.A market correction is defined as a major index falling 10% from its most recent peak.The ASX 200 narrowly avoided a correction last month after it fell 9.43% from its record high on 14 February to a trough on 13 March.The fall saw several blue-chip sharestrading at multi-year lows, including Fortescue Ltd  and CSL Ltd .The ASX 200 began a rebound on 14 March, but this week's US tariffs news has brought that undone.The ASX 200 closed down 10.38% from its 14 February high today.Today, we heard from more companies about the potential impact of the tariffs on their operations.ASX 200 dives into official correction as more companies reveal US tariff impact. The ASX 200 biotec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/04/asx-200-plunges-as-us-tariffs-fall-out-continues/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","BK7507","BK7067","BRG.AU","BK7051","BK7129","BK7508","ANN.AU","BK7119","CSL.AU","BK7126","FMG.AU","AOV.AU","BK7511","MSB.AU","BK7501"],"gpt_icon":0},{"id":"2524478612","title":"Friday’s HotCopper Trends: Mesoblast dodges tariffs, Orthocell’s FDA tick | April 4, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524478612","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524478612?lang=en_us&edition=fundamental","pubTime":"2025-04-04 09:57","pubTimestamp":1743731820,"startTime":"0","endTime":"0","summary":"The ASX has been down 1.5% at 7,739 points this morning.There’s been carnage on the ASX and the Energy sector has been enduring a bloodbath, followed by IT and Utilities.Staples and Health Care are the only sectors in positive territory so far.In company news, Mesoblast  has been among the most watched on HotCopper forums today after the medicinal company confirmed its belief its products will not be subject to United States tariffs.Orthocell  has also been trending on news the US FDA has given the green light for the company’s nerve repair product, Remplir, to be sold in the States.And, finally, Bellevue Gold  has provided an update saying it’s not yet in a position to make an announcement about the potential downward adjustment to its FY25 production guidance.Levy beef: Trump whacks Oz with 10% tariffs on “Liberation Day”。The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/fridays-hotcopper-trends-mesoblast-dodges-tariffs-orthocells-fda-tick-april-4-2025-2025-04-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BGL.AU","BK4139","BK7508","BK7104","BK7501","MESO","OCC.AU","MSB.AU","BK7067"],"gpt_icon":0},{"id":"2524124544","title":"BRIEF-Mesoblast Says Mesoblast Cell Therapy Products Not Subject To U.S. Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2524124544","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524124544?lang=en_us&edition=fundamental","pubTime":"2025-04-04 08:15","pubTimestamp":1743725743,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Says Mesoblast Cell Therapy Products Not Subject To U.S. TariffsApril 4  - Mesoblast Ltd MSB.AX:MESOBLAST CELL THERAPY PRODUCTS NOT SUBJECT TO U.S. TARIFFSCELL THERAPY PRODUCTS NOT SUBJECT TO U.S. TARIFFSALLOGENEIC CELLULAR PRODUCTS, INCLUDING RYONCIL AND REVASCOR, WILL NOT BE SUBJECT TO TARIFFSFurther company coverage: MSB.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QH173:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MESO","MSB.AU","BK7067","BK7508","BK7501"],"gpt_icon":0},{"id":"2524248874","title":"Mesoblast Says Products Exempt From US Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2524248874","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524248874?lang=en_us&edition=fundamental","pubTime":"2025-04-04 07:14","pubTimestamp":1743722066,"startTime":"0","endTime":"0","summary":"Mesoblast  said that its allogeneic cellular products will not be impacted by the US government's recently implemented tariffs on imported goods, according to a Friday filing with the Australian bourse.The company clarified that these products are derived from US donors and are classified as US-origin, making them exempt from the tariffs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7501","BK7067","BK7508","MESO","BK4139","XJO.AU","XAO.AU","MSB.AU"],"gpt_icon":0},{"id":"2524210636","title":"BRIEF-Mesoblast Says Allogeneic Cell Therapy Products Are Designated ‘U.S. Country Of Origin’ And Not Subject To U.S. Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2524210636","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524210636?lang=en_us&edition=fundamental","pubTime":"2025-04-04 07:00","pubTimestamp":1743721201,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Says Allogeneic Cell Therapy Products Are Designated ‘U.S. Country Of Origin’ And Not Subject To U.S. TariffsApril 3 (Reuters) - Mesoblast Ltd MSB.AX:MESOBLAST ALLOGENEIC CELL THERAPY ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH1H5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","BK4139","BK7067","BK7501","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2524217028","title":"Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2524217028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524217028?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:59","pubTimestamp":1743721140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH1H5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","MSB.AU","BK4139","BK7508","MESO"],"gpt_icon":0},{"id":"2524217359","title":"Mesoblast Ltd - Cell Therapy Products Not Subject to U.S. Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2524217359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524217359?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:33","pubTimestamp":1743719606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH173:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK4139","MSB.AU","BK7501","BK7067","MESO"],"gpt_icon":0},{"id":"2524173542","title":"Mesoblast - Allogeneic Cellular Products, Including Ryoncil and Revascor, Will Not Be Subject to Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2524173542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524173542?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:33","pubTimestamp":1743719606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH173:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK4139","MSB.AU","BK7067","MESO"],"gpt_icon":0},{"id":"2524478432","title":"Mesoblast Seeks US FDA Meeting to Discuss Approval for Heart Failure Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2524478432","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524478432?lang=en_us&edition=fundamental","pubTime":"2025-04-03 09:56","pubTimestamp":1743645382,"startTime":"0","endTime":"0","summary":"Mesoblast  requested a Type B meeting with the US Food and Drug Administration to discuss the accelerated approval pathway for its drug candidate, Revascor, in treating ischemic chronic heart failure, according to a Thursday filing with the Australian bourse.The meeting will focus on key aspects of the approval process, including manufacturing, potency assays, and confirmatory trial design, the filing said.The meeting is expected to take place this quarter, the filing added.Shares of the company fell nearly 2% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MESO","BK7067","MSB.AU","BK7501","BK7508"],"gpt_icon":0},{"id":"2524942872","title":"Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2524942872","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524942872?lang=en_us&edition=fundamental","pubTime":"2025-04-03 07:15","pubTimestamp":1743635700,"startTime":"0","endTime":"0","summary":"NEW YORK, April 02, 2025  -- Mesoblast , global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug Administration  to discuss the accelerated approval pathway for Revascor  in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction  and inflammation.In a Type B meeting last year, FDA provided guidance to Mesoblast that the company was eligible to file for accelerated approval of REVASCOR in patients with end-stage HFrEF based on the totality of data across two randomized controlled trials. FDA also guided that a single confirmatory trial in class II/III patients with ischemic HFrEF and inflammation will need to be completed after any accelerated approval is obtained.The key objectives of the meeting are to obtain FDA feedback on relevant chemistry, manufacturing & controls , alignment on potency assays for commercial product release, and Mesoblast’s pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-files-request-type-b-231500036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4575","BK4150","BK4139","MSB","LU0267386448.USD","LU0170899867.USD","LU0971096721.USD","IE00BKVL7J92.USD","BK4006","IE00B1BXHZ80.USD","CMC","IE00BHPRN162.USD","LU0882574139.USD","MSB.AU","LU1363072403.SGD","MESO","IE00BZ1G4Q59.USD","MSC","LU0149725797.USD"],"gpt_icon":0},{"id":"2524417166","title":"Mesoblast (ASX:MSB) Announces Ryoncil Availability But Sees 15% Price Drop Over Past Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2524417166","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524417166?lang=en_us&edition=fundamental","pubTime":"2025-04-03 01:46","pubTimestamp":1743615988,"startTime":"0","endTime":"0","summary":"Mesoblast recently announced the availability of its groundbreaking therapy, Ryoncil, in the United States, yet its share price experienced a 15% decline over the past week. This downturn occurred despite the company's significant progress in healthcare innovation, following its inclusion in the S&P/ASX 200. External factors, like the volatile global market reacting to geopolitical concerns, also contributed to this decline, as broader market indices showed a mixed performance with rising volatility. These market pressures alongside rising uncertainty about new tariffs potentially impacted investor sentiment and influenced Mesoblast's share price performance adversely.View our complete analysis and fair value estimate and you decide.Over the last year, Mesoblast's shares have delivered a striking total return of 111.86%. This performance significantly outperformed both the Australian Biotechs industry, which saw a 7.7% decline, and the broader Australian market, which experienced a 1.7","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-asx-msb-announces-ryoncil-174628204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","MESO","MSB.AU","MSB","BK4139"],"gpt_icon":0},{"id":"2523934123","title":"BRIEF-Mesoblast Says Co Entered Medicaid National Drug Rebate Agreement With US CMS For Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2523934123","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523934123?lang=en_us&edition=fundamental","pubTime":"2025-03-31 09:31","pubTimestamp":1743384673,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Says Co Entered Medicaid National Drug Rebate Agreement With US CMS For RyoncilMarch 31 (Reuters) - Mesoblast Ltd MSB.AX:ENTERED INTO MEDICAID NATIONAL DRUG REBATE AGREEMENT WITH U.S. CMS FOR RYONCILFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC05Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","BK7067","BK7501","MSB.AU","BK7508","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":165,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[]}}